rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
5
|
pubmed:dateCreated |
1997-12-11
|
pubmed:abstractText |
We have previously found that conformal radiation therapy (RT) and hepatic arterial fluorodeoxyuridine was associated with durable responses and long-term survival for patients treated for nondiffuse primary hepatobiliary tumors and colorectal liver metastases. Further improvements in hepatic control may result from the addition of selective radiosensitization using bromodeoxyuridine (BrdU) infused through the hepatic artery (HA) concurrently with RT. This is a Phase I study of escalating doses of HA BrdU combined with our standard hepatic RT.
|
pubmed:grant |
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0360-3016
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
39
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1087-92
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:9392548-Adult,
pubmed-meshheading:9392548-Aged,
pubmed-meshheading:9392548-Bile Duct Neoplasms,
pubmed-meshheading:9392548-Bile Ducts, Intrahepatic,
pubmed-meshheading:9392548-Bromodeoxyuridine,
pubmed-meshheading:9392548-Carcinoma, Hepatocellular,
pubmed-meshheading:9392548-Cholangiocarcinoma,
pubmed-meshheading:9392548-Colonic Neoplasms,
pubmed-meshheading:9392548-Drug Administration Schedule,
pubmed-meshheading:9392548-Female,
pubmed-meshheading:9392548-Hepatic Artery,
pubmed-meshheading:9392548-Humans,
pubmed-meshheading:9392548-Infusions, Intra-Arterial,
pubmed-meshheading:9392548-Liver Neoplasms,
pubmed-meshheading:9392548-Male,
pubmed-meshheading:9392548-Middle Aged,
pubmed-meshheading:9392548-Radiation-Sensitizing Agents,
pubmed-meshheading:9392548-Radiotherapy Dosage,
pubmed-meshheading:9392548-Rectal Neoplasms
|
pubmed:year |
1997
|
pubmed:articleTitle |
A phase I trial of hepatic arterial bromodeoxyuridine and conformal radiation therapy for patients with primary hepatobiliary cancers or colorectal liver metastases.
|
pubmed:affiliation |
Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|